---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-22-000051"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T01:06:13.332921+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences reports Q3 2022 GAAP EPS $0.60, adjusted EPS $0.86; raises FY adjusted EPS guidance

## Summary
- Q3 revenues $385M (-0.4% reported, +3.5% organic); GAAP EPS $0.60 (vs $0.51), adjusted EPS $0.86 (flat YoY).
- Codman Specialty Surgical rev $249.8M (-2.6% reported, +1.6% organic); Tissue Technologies rev $135.4M (+3.9% reported, +7.2% organic).
- Raised FY2022 adjusted EPS guidance to $3.29-$3.33; reaffirmed rev $1,551M-$1,563M with organic growth 3.7%-4.5%.
- Completed TWC divestiture to Gentell for $28.8M ($27.8M cash + $1M contingent consideration).
- CereLink recall provision $1.5M, rework $0.8M; return-to-market expected 1H2023.

## SEC filing metadata
- accession: 0000917520-22-000051
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752022000051/0000917520-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752022000051/iart-20221026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-22-000051
- JSON: https://secwatch.observer/filing/0000917520-22-000051.json
- Plain text: https://secwatch.observer/filing/0000917520-22-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.